

# NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included. Medicines included are consistent across the health board.

## How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

## What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Appraisals (NICE MTAs) are applicable in Scotland.

## What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

## Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC on their preferred medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

<p><b>Abrocitinib</b> tablets Cibinqo® SMC2431</p>	<p>Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.</p>	<p>Routinely available in line with national guidance</p>	<p>13/06/2022</p>
<p><b>Belimumab</b> injection injection in pre-filled pen SMC2483</p>	<p>In combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>13/06/2022</p>
<p><b>Bempedoic acid</b> tablets Nilemdo® SMC2363</p>	<p>Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - In combination with a statin, or a statin with other lipid-lowering therapies in patients unable to reach low-density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or -Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contra-indicated.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Bempedoic acid with Ezetimibe</b> tablets Nustendi® SMC2406	Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe, - alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone - in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin.	Routinely available in line with local or regional guidance	13/06/2022
<b>Berotrastat</b> capsules Orladeyo® SMC2405	Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.	Routinely available in line with national guidance	13/06/2022
<b>Blinatumomab</b> infusion Blincyto® SMC2468	Monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.	Not routinely available as not recommended for use in NHSScotland	13/06/2022

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Carfilzomib</b> infusion Kyprolis® SMC2484</p>	<p>In combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>13/06/2022</p>
<p><b>Cemiplimab</b> infusion Libtayo® SMC2489</p>	<p>As monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: - locally advanced NSCLC who are not candidates for definitive chemoradiation, or - metastatic NSCLC</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>13/06/2022</p>
<p><b>Dapagliflozin</b> tablets Forxiga® SMC2428</p>	<p>In adults for the treatment of chronic kidney disease.</p>	<p>Routinely available in line with national guidance</p>	<p>13/06/2022</p>
<p><b>Daratumumab</b> injection Darzalex® SMC2469</p>	<p>Combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>13/06/2022</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Daratumumab</b> injection Darzalex® SMC2416</p>	<p>In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>13/06/2022</p>
<p><b>Dostarlimab</b> infusion Jemperi® SMC2404</p>	<p>Monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>
<p><b>Emtricitabine, tenofovir anafenamide</b> tablets Descovy N/A</p>	<p>Pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk men who have sex with men, including adolescents (with body weight at least 35 kg)</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>
<p><b>Fedratinib</b> capsules Inrebic® SMC2462</p>	<p>Treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Filgotinib</b> tablets Jyseleca® SMC2467	Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.	Routinely available in line with national guidance	13/06/2022
<b>Givosiran</b> injection Givlaari® SMC2470	Treatment of acute hepatic porphyria in adults and adolescents aged 12 years and older.	Not routinely available as not recommended for use in NHSScotland	13/06/2022
<b>Hydrocortisone</b> MR capsules Efmody® SMC2414	Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.	Not routinely available as not recommended for use in NHSScotland	13/06/2022
<b>Ibrutinib</b> tablets Imbruvica® SMC2485	In combination with rituximab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.	Not routinely available as not recommended for use in NHSScotland	13/06/2022

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Inclisiran</b> injection Leqvio® SMC2358	Treatment for adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients who are unable to reach LDL-C goals with the maximum tolerated dose of a statin, or - alone or in combination with other lipid lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.	Routinely available in line with local or regional guidance	13/06/2022
<b>Ixekizumab</b> pre-filled syringe, pen Taltz® SMC2440	Ankylosing spondyloarthritis (radiographic axial spondyloarthritis) Treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. Non-radiographic axial spondyloarthritis Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).	Not routinely available as not recommended for use in NHSScotland	13/06/2022
<b>Lenvatinib</b> capsules Kisplyx® SMC2476	Treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line treatment	Routinely available in line with local or regional guidance	13/06/2022

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Liraglutide</b> injection <b>Saxenda®</b> SMC2455	as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of: - $\geq 30\text{kg/m}^2$ (obese), or - $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 12/12/2022	13/06/2022
<b>Mepolizumab</b> injection <b>Nucala®</b> SMC2491	Add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.	Not routinely available as not recommended for use in NHSScotland	13/06/2022
<b>Mepolizumab</b> injection <b>Nucala®</b> SMC2488	Add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.	Not routinely available as not recommended for use in NHSScotland	13/06/2022
<b>Mepolizumab</b> injection <b>Nucala®</b> SMC2490	As an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA).	Not routinely available as not recommended for use in NHSScotland	13/06/2022



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Nivolumab</b> infusion</p> <p>Opdivo®</p> <p>SMC2429</p>	<p>Monotherapy for the adjuvant treatment of adult patients with completely resected oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>
<p><b>Oritavancin</b> infusion</p> <p>Tenkasi®</p> <p>SMC2285</p>	<p>Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.</p>	<p>Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative</p>	<p>13/06/2022</p>
<p><b>Pembrolizumab</b> infusion</p> <p>Keytruda®</p> <p>SMC2420</p>	<p>In combination with platinum and fluoropyrimidine based chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS≥10.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>
<p><b>Ponesimod</b> tablets</p> <p>Ponvory®</p> <p>SMC2384</p>	<p>Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.</p>	<p>Routinely available in line with national guidance</p>	<p>13/06/2022</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Relugolix, estradiol, norethisterone</b> tablets Ryeqo® SMC2442	Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  12/12/2022	13/06/2022
<b>Risankizumab</b> injection Skyrizi® SMC2459	Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).	Routinely available in line with national guidance	13/06/2022
<b>Ropeginterferon alfa-2b</b> injection Besremi® SMC2421	Monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.	Not routinely available as not recommended for use in NHSScotland	13/06/2022
<b>Ruxolitinib</b> tablets Jakavi® SMC2498	treatment of: - patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids - patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids	Not routinely available as not recommended for use in NHSScotland	13/06/2022

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Sacituzumab</b> infusion</p> <p>Trodely®</p> <p>SMC2446</p>	<p>Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>
<p><b>Solriamfetol</b> tablets</p> <p>Sunosi®</p> <p>SMC2419</p>	<p>To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>13/06/2022</p>
<p><b>Sotorasib</b> tablets</p> <p>Lumykras®</p> <p>SMC2443</p>	<p>Monotherapy for the treatment of adult patients with KRAS G12C-mutated, locally advanced or metastatic, non-small cell lung cancer (NSCLC), who have progressed on, or are intolerant to platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>
<p><b>Tepotinib</b> tablets</p> <p>Tepmetko®</p> <p>SMC2457</p>	<p>treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>13/06/2022</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Upadacitinib</b> tablets Rinvoq® SMC2417</p>	<p>Treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.</p>	<p>Routinely available in line with national guidance</p>	<p>13/06/2022</p>
<p><b>Venetoclax</b> tablets Venclyxto® SMC2412</p>	<p>In combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>
<p><b>Venetoclax</b> tablets Venclyxto® SMC2427</p>	<p>In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).</p>	<p>Routinely available in line with local or regional guidance</p>	<p>13/06/2022</p>
<p><b>White birch betula verrucosa extract</b> oral lyophilisate Itulazax 12 SQ-Bet® SMC2471</p>	<p>In adult patients for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. ITULAZAX is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE).</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>13/06/2022</p>